|
AIDS - A Biological Weapon
An interview on Radio Liberty. Are you viewing this page ONLINE?
The URL of this page is: www.Net4TruthUSA.com/AIDSCure.htm
You may link to this page from your web site.
www.RadioLiberty.com (archived program).
Used with permission.
You can obtain a free PDF copy of this article, along with a
reproduction of the US patent paper (reproduced below) by clicking on:
www.Net4TruthUSA.com/AIDScure.htm
To verify that this patent is actually on
file with the US Patent Office (and I am not posting this as a
hoax), go to www.uspto.gov click on Patent Search and enter
Patent #5676977
You may distribute this article in either printed or electronic (PDF
file) format, as long as it is distributed in its entirety. See the
copyright notice on: www.Net4ruthUSA.com/CondCopyright.htm
A U.S. PATENT FOR AN AIDS CURE?
Where did the AIDS virus come from? In recent decades, we have seen a
flurry of new diseases such as E-Bola
Zaire (incurable flesh-eating virus),
Lymphogranuloma Inguinale (a form of virulent lymph cancer - see my book
"Land of Childhood's Fears" on www.Net4TruthUSA.com/VietnamBook.htm),
Lyme disease (possible bio-release from US DOD facility off
the coast of Lyme, CT.), West Nile virus,
a "super-strain" of AIDS, and a host of others never before recorded in
human history.
With medical science's effectiveness in curing past killers (Polio, Reubella, Smallpox, et al.),
could it be that there are other people with the obverse agenda? (i.e.:
to create diseases in order to kill people)?
No doubt there are people who believe in "population control", and for
that, read "mass genocide", or at least a "thinning of the herd" from
their sick perspective. Jacques Cousteau has been quoted as advocating
the "elimination" of 350,000 people a day, until the Earth
reaches an "optimum" population "under half a billion" -
as per the commandments written on the Georgia Guide Stones.
It is a little-known fact that Adolf Hitler borrowed his
idea for his "Master Race" from Margaret Sanger and her
infanticide organization "Planned Parenthood", which sponsors millions
of baby-murders around the world funded in large part with our tax
dollars. Research into this nefarious organization will expose it for
what it really is; and I'll leave that "enlightenment" for you to pursue
on your own - because you wouldn't believe me if I just came out and
spoke the truth. DO THE RESEARCH, AND LEARN THE TRUTH FOR YOURSELF -
Then I can say that I just pointed you in the direction of the evidence,
but you came to your own conclusions.
The Masons, and
Skull and Bones (Illuminati) have a "New World Order" agenda,
and their own set of "commandments" for their imagined "utopia". Look up
the Georgia Guide Stones with your favorite search engine.
Is it possible that the US Government has secret biological laboratories
devoted to the development of pathogens and biological agents that are
specifically targeted to certain segments of the population? It would
seem that such is the case, from overwhelming evidence uncovered
recently.
A lawsuit pending in Federal court in California, charges the US
government with developing a "Synthetic
Biological Agent / Weapon". The plaintiff is also pursuing
issues into the World Criminal Courts.
AIDS started to spread in the homosexual community in San Francisco in the late 60s and 70s
- and the plaintiff alleges that there is a
"cause and effect relationship" where recipients of certain
vaccines developed AIDS.
If the government has developed a pathogen with the intention of
infecting certain segments of the world's population for "experimental"
or "population control" purposes, it wouldn't be the first time. Those
who have studied their history will be familiar with the Tuskegee
syphilis experiment, et al. Korean War and Vietnam War veterans
were knowingly exposed to 2, 4-D paraquat (Agent Orange), and Gulf War
soldiers are being exposed to
depleted uranium and other biological
pathogens (See the "Ill Wind"
issue of Freedom Magazine available
free on www.FreedomMag.org).
The United States Patent office has on file, the following patent
description for an AIDS cure. I must admit that the language and
terminology contained in the patent text is beyond my ability to
comprehend, since I am neither a doctor, a biologist, nor a virologist.
However, anyone who has ever dealt with the US Patent Office knows that
patents are not issued on hair-brained theories; the product to be
patented must be demonstrated to work, and must be unique among other
inventions or products of its type. The "invention" must pass the test
of efficacy and functionality to the satisfaction of patent examiners
and lawyers, or its efficacy and functionality must be demonstrated or
obvious in fact.
AIDS Cure Patent #5676977 is filed with the US Patent
Office. See: www.uspto.gov (US Patent
& Trademark Office)
Also see: Public Law #
91-213 signed by President Nixon on March 16, 1970
If the US government has effectively endorsed a product as effective by
issuing a patent, then why is not the cure for this scourge available?
Certainly, the big drug companies could reap windfall profits worldwide
by offering an effective product to those who are dying from this
affliction. I should think a "one shot" cure for AIDS could bring
whatever price the market could bear, and those who are on death's door
would go to any extreme - including traveling outside the US, and
/ or breaking the law to get the cure.
Obviously, to a critical thinker, one of three things must be true here:
1 - There IS no AIDS cure, and the patent is a mistake or a hoax.
2 - There IS in fact a cure, the patent is valid, and the
government (FDA?) is suppressing its distribution (You would think
something like a PATENTED CURE for AIDS would have made the NEWS!)
3 - The inventor of the cure is not licensing or making his
product available (reasons unknown), which as the owner, he is legally
entitled to do.
With so many lives at stake, the question "Why?" must be answered. At
this point, there is precious little information available to me other
than what I have posted here. Doctor Stan Monteith of Radio Liberty has
written a book titled, "AIDS - The Unnecessary
Epidemic", which is useful and informative. You can get the
book from his web site at
http://www.radioliberty.com/baids.htm or call (831) 475-6651
To contact the guest appearing on this radio program, or for additional
information, send e-mail to: boyded2003@Yahoo.com
PLEASE TELL HIM YOU FOUND THIS INFORMATION ON:
www.Net4TruthUSA.com
THE FOLLOWING IS A VERBATIM REPRODUCTION OF THE US PATENT
FILING AS IT APPEARS IN THE US PATENT OFFICE. CLICKING THE "Direct Link
to Page" will take you directly to the Patent Office web site where this
document appears. The text is slightly reformatted here for pagination
and neatness of appearance. The TABLE is as is on the USPTO web
site (although it is incomprehensible to me).
United States Patent
Patent # 5,676,977
Antelman October 14, 1997
--------------------------------------------------------------------------------
Direct link to page on PATENT OFFICE
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=5676977.WKU.&OS=PN/5676977&RS=PN/5676977
Method
of curing AIDS with tetrasilver tetroxide molecular crystal devices
Abstract
The diamagnetic semiconducting molecular crystal
tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the
AIDS virus, destroying AIDS synergistic pathogens and immunity
suppressing moieties (ISM) in humans. A single intravenous injection of
the devices is all that is required for efficacy at levels of about 40
PPM of human blood. The device molecular crystal contains two mono and
two trivalent silver ions capable of "firing" electrons capable of
electrocuting the AIDS virus, pathogens and ISM. When administered into
the bloodstream, the device electrons will be triggered by pathogens, a
proliferating virus and ISM, and when fired will simultaneously trigger
a redox chelation mechanism resulting in divalent silver moieties which
chelate and bind active sites of the entities destroying them. The
devices are completely non-toxic. However, they put stress on the liver
causing hepatomegaly, but there is no loss of liver function.
--------------------------------------------------------------------------------
Inventors: Antelman; Marvin S. (Rehovot, IL)
Assignee: Antelman Technologies Ltd. (Providence,
RI)
Appl. No.: 658955
Filed: May 31, 1996
Current U.S. Class: 424/618; 514/495
Intern'l Class: A61K 033/38
Field of Search: 424/618 514/495
--------------------------------------------------------------------------------
References Cited [Referenced By]
--------------------------------------------------------------------------------
U.S. Patent Documents
4415565
Nov., 1983 Wysor
424/618.
4915955 Apr., 1990 Gomori
424/616.
4952411 Aug., 1990 Fox, Jr. et al.
424/618.
5073382 Dec., 1991 Antelman
424/604.
5078902 Jan., 1992 Antelman
424/618.
5089275 Feb., 1992 Antelman
424/602.
5211855 May., 1993 Antelman
424/618.
5223149 Jun., 1993
Antelman 424/618.
5336499 Aug., 1994
Antelman 424/405.
5571520 Nov., 1996
Antelman 424/618.
Other References
"Is The AIDS Virus A Science Fiction?" by Peter H. Duesberg and Bryan J. Ellison, Policy Review, Summer 1990,
pp. 40-51.
Primary Examiner: Hulina; Amy
Attorney, Agent or Firm: Salter & Michaelson
--------------------------------------------------------------------------------
Parent Case Text
--------------------------------------------------------------------------------
This application is a continuation-in-part of patent
application Ser. No. 08/310,859 filed Sep. 22, 1994, now abandoned.
--------------------------------------------------------------------------------
Claims
--------------------------------------------------------------------------------
What is claimed is:
1. A method of treating AIDS-afflicted humans comprising
injecting a multitude of tetrasilver tetroxide molecular crystals into
the bloodstream of the human subject.
2. A method for increasing white blood cell counts in
AIDS-afflicted humans comprising injecting a multitude of tetrasilver
tetroxide molecular crystals into the bloodstream of the human subject.
3. Methods of treating AIDS-affilicted humans according
to claims 1-2 where the concentration of said molecular crystals is
approximately 40 PPM of the total blood weight of the human subject.
--------------------------------------------------------------------------------
Description
--------------------------------------------------------------------------------
BACKGROUND OF THE INVENTION
The present invention relates to the employment of
molecular crystals as anti-AIDS devices, but more particularly to the
molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4
which has two monovalent and two trivalent silver ions per molecule, and
which through this structural configuration enables intermolecular
electron transfer capable of killing viruses and binding them to the
resulting silver entity so that a single intravenous injection will
completely obliterate acquired immune deficiency syndrome (AIDS) in
humans. Furthermore, said devices are capable of killing pathogens and
purging the bloodstream of immune suppressing moieties (ISM) whether or
not created by the AIDS virus (HIV); so as to restore the immune system.
The present invention is based on concepts previously
elucidated in applicant's U.S. Pat. No. 5,336,499 which discloses the
destruction and inhibition of bacteria, algae and the AIDS virus in
nutrient life supporting systems by using said silver oxide devices.
Example 3 of said patent discloses that 18 PPM of said crystal devices
could totally suppress the AIDS virus (page 6, line 5). Subsequent to
the filing of the aforementioned patent, further testing revealed
complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the
fact that said devices were harmless when ingested and inhaled, being
non-toxic.
Encouraged by these evaluations and successes, applicant
obtained permission to evaluate the crystals in vitro against murine
acquired immune deficiency syndrome (MAIDS). Only one facility in the
State of Israel is licensed for these evaluations, namely, the Kaplan
Hospital in Rehovot, Israel, which is affiliated with the Hebrew
University-Hadassah Medical School where said evaluations were done.
The initial evaluations entailed experimenting with
various silver moieties cited in applicant's aforementioned patent,
concentrations, non-reactive buffers and modes of administration. After
about 18 months of judicious efforts and initial failures, success was
finally achieved in destroying the MAIDS virus in C57BL mice with a
single intravenous injection. The results of this test program comprise
Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the
inventor was able to test the efficacy of said devices on two select
etiological groups of terminal AIDS patients in a clinic in Tegucigalpa,
Honduras, Central America.
The AIDS patients comprised the etiological subgroups,
Candidiasis and Wasting Syndrome. Current indicator diseases for
diagnosing AIDS which have been expanded by the CDC, fall into the
following five major categories with the approximate percent
distribution among AIDS patients:
______________________________________
1. P. carinii pneumonia
51%
2. Wasting syndrome
19%
3. Candidiasis
13%
4. Kaposi's sarcoma
11%
5. Dementia
6%
______________________________________
This invention concerns itself with the treatment and
cure of candidiasis and wasting syndrome AIDS patients with Tetrasil*.
These two groups account for approximately one third of AIDS cases.
*Trademark of Holipharm Corporation (of Israel) for
Ag.sub.4 O.sub.4
Stedman's Medical Dictionary (Williams & Wilken's 26th
Ed., 1995) defines wasting syndrome "as a condition of 10% weight loss
in conjunction with diarrhea or fever . . . Associated with AIDS (p.
1744)."
OBJECTS OF THE INVENTION
The main object of the invention is to provide for a
molecular scale device of a single tetrasilver tetroxide crystalline
molecule capable of restoring the immunity of AIDS afflicted humans of
the two AIDS etiological subgroups, candidiasis and wasting syndrome.
Another object of the invention is to provide for
immunity restoration in said AIDS afflicted humans through a single
injection.
Another object of this invention is to destroy ISM in
humans manifesting AIDS diseases of said AIDS etiological subgroups
irrespective as to whether said ISM was HIV induced, since it is known
that humans may manifest AIDS and still be HIV negative, and thus
restore the immune system in said humans.
Another object of this invention is to destroy the AIDS
virus when present in the systems of said AIDS afflicted humans.
SUMMARY OF THE INVENTION
This invention relates to a molecular scale device not
only capable of destroying the AIDS virus, but of purging the human
bloodstream of pathogens and restoring immunity to AIDS patients of the
candidiasis and wasting syndrome categories. Said molecular device
consists of a single crystal of tetrasilver tetroxide (Ag.sub.4
O.sub.4). The crystal lattice of this molecule has a unique structure
since it is a diamagnetic semiconducting crystal containing two mono and
two trivalent silver ions, which in effect are capable of "firing"
electrons under certain conditions which will destroy AIDS viruses,
other pathogens and immune suppressing moieties (ISM), not only through
the electrocution mode, but also by a binding process which occurs
simultaneously with electron firing, namely, binding and chelation of
divalent silver, i.e., the resulting product of the electron transfer
redox that occur when the monovalent silver ions are oxidized and the
trivalent ions are reduced in the crystal. The binding/chelation effect
occurs at active sites of the AIDS virus, pathogens and ISM. Because of
the extremely minute size of a single molecule of this crystal, several
million of these devices may be employed in concert to destroy a virus
colony to purge a life support system of ISM and pathogens with the
consumption of only parts per trillion of the crystal devices. Thus an
optimum of 40 PPM of the devices by weight of human blood was found to
be sufficient to completely obliterate AIDS. This concentration is
slightly over double of the optimum concentration recommended in
applicant's aforementioned U.S. patent for the destruction of the human
AIDS virus in vitro. Other details concerning the structure of the
crystal and its mechanism against pathogens, the AIDS virus and ISM
would analogously hold here, and have already been further elucidated in
said patent.
The actual destruction of pathogens, ISM and the AIDS
virus is effectuated by injection of a suspension of these devices in
distilled or deionized water with a non-reacting electrolyte directly,
i.e. intravenously, into the bloodstream. A single injection is all that
is required under these conditions. Accordingly, humans injected in this
manner, upon being inspected after three weeks or more had elapsed and
compared with similar humans that had been given placebos, were
completely cured of AIDS. The control group still manifested AIDS.
Accordingly, the tetrasilver tetroxide device performed in concert with
and in full conformity with the ultimate objects of this invention.
Furthermore, three out of four wasting syndrome terminal patients and
four out of the five candidiasis terminal patients were still alive in
1995 after a year and a half had elapsed from their initial injection.
By that time all the AIDS patients had been released from the clinic and
allowed to return home.
Other objects and features of the present invention
shall become apparent to those skilled in the art when the present
invention is considered in view of the accompanying examples. It should,
of course, be recognized that the accompanying examples illustrate
preferred embodiments of the present invention and are not intended as a
means of defining the limits and scope of the present invention.
EXAMPLE 1
Five patients afflicted with AIDS of the candidiasis
etiological category were segregated for Tetrasil treatment. The
rationale for selecting them was based on facts presented in an article
by Peter H. Duesberg and Brian J. Ellison entitled "Is The AIDS Virus A
Science Fiction?" (Policy Review, Summer 1990 pp. 40-51). Only the
factual presentations of the article were utilized and the hypothesis of
the authors was ignored. The facts presented in the article related to
the method of selecting AIDS patients based on the five aforementioned
etiological subgroups targeted by the CDC, and the evidence presented,
that there is AIDS without HIV as well as with it so that an anti-viral
agent in most instances will not necessarily restore the immunity
system.
Evaluations with Tetrasil were conducted on AIDS
patients at Lucha Contra el Sida, Comayaguela, Honduras. The patients
two weeks prior to inoculation were removed from their AZT, AIDS
therapy. Tetrasil was administered at approximately 40 PPM of blood
volume per patient as a suspension in a proprietary buffer solution
(pH=6.5), supplied by Holipharm Corporation.
The results of evaluations with candidiasis are
tabulated in Table I under its disease category. All patients evaluated
were terminal. Some, however, were in moderate (m) condition and others
in poor (p) as designated in the Table. The I and F designations refer
to initial and final values as shown. WBC indicates white cell blood
count. The H column, following CD 8, indicates whether hepatomegaly
occurred. This was an unfortunate consequence of the treatment which
resulted in enlarged livers in all patients except the second one.
Despite hepatomegaly, there was no interference with liver function.
The onset of hepatomegaly was not spontaneous and varied
from patient to patient, being in the range of 4-16 days.
It should also be noted that shortly after injection of
Tetrasil there were indications of fever (symbolized by T in the
Ag.sub.4 O.sub.4 column), sometimes accompanied by fatigue (F). The body
temperature was invariably 38.5.degree. C. (101.3.degree. F.). This was
indicative of restoration of the immune response of the body, since
normally the body will destroy pathogens when the immune system is
functional by raising the temperature. The patient who died; first
responded favorably to Diflucan, which previously gave no response. He
was cured of his candidiasis, but unfortunately succumbed to his
previous body damage. All the other candidiasis syndrome people who
previously did not respond to the indicated medications subsequently
responded after the Tetrasil treatment. Further evidence of the recovery
of the AIDS patients manifested itself 30 days after the initial
injection when white blood cell counts were taken. They are shown in
Table I under the WBC column, which gives the initial and final WBC. All
candidiasis patients showed a dramatic increase in their white blood
cell counts, indicative of the restoration of their immunity systems.
EXAMPLE 2
The above protocol of Example 1 was repeated with AIDS
patients exhibiting wasting syndrome. The results of their treatment are
tabulated in Table I under the disease category of said syndrome. It
should be noted that two of the four wasting syndrome patients showed
improved white blood counts. The female patient, whose condition
improved from poor and terminal to be among the living, showed a
decrease in the WBC. However, she showed an increase in body temperature
which was indicative of immune response. The test results indicate that
one cannot rely on a single factor to indicate the demise of AIDS. The
usual HIV marker CD 4 initial and final are irrelevant. ISM suppression
appears to be more critical than the destruction of HIV. AIDS was
suppressed, any permanent damage that had been done to the patients in
the course of their succumbing to AIDS was not obviously cured or
corrected by said crystal device treatment, rather said injury persisted
and the patient was improved with respect to AIDS but still suffered
from said permanent injury or impairment previously inflicted.
TABLE I
__________________________________________________________________________
Response of AIDS Patients to Single 40 PPM Ag.sub.4 O.sub.4 Inoculation
Date
Weight
DISEASE
PATIENT Inoc.
WBC CD 4 DEATH
Lbs.
Group Sex
Age
Medictn
1994
I F I F CD 8
H 1944
I F Ag.sub.4 O.sub.4
__________________________________________________________________________
Candidiasis
M p
28 Diflucan
5/5
1,200
4,200
41
-- 221
+ 6/11
82 76
T
F m
33 " 5/5
6,000
6,700
554
872
394
- 98 98
T
F m
33 Ketaconzl
5/27
2,600
3,850
248
181
951
+ 123 123
T
M p
62 " 6/2
3,300
3,700
89
237
59
+ 105 92
F
F m
31 Pentamidn
6/2
2,400
3,050
9 181
65
+ 121 118
Pain
Wasting
M m
27 5/27
3,600
4,600
39
14
709
+ 119 120
T
Syndrome
M m
28 5/27
2,750
-- 10
-- 60
+ 7/19
121 119
T, F
F p
43 5/27
3,600
2,700
68
246
248
+ 101 98
T, F
M m
19 5/10
3,850
5,400
137
36
48
+ 103 106
T, F
__________________________________________________________________________
As this
invention may be embodied in several forms without departing from the
spirit or essential characteristics thereof, the present embodiments are
therefore illustrative and not restrictive, since the scope of the
invention is defined by the appended claims rather than by the
description preceding them, and all changes that fall within the metes
and bounds of the claims or that form their functional as well as
conjointly cooperative equivalents, are therefore intended to be
embraced by these claims.
۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩۩
FOOTNOTE
|
